Literature DB >> 11774172

High proliferative activity may predict early metastasis of thin melanomas.

S O Frahm1, C Schubert, R Parwaresch, P Rudolph.   

Abstract

Metastasis of thin melanomas is uncommon and unpredictable. We prospectively investigated the clinical course of 167 thin melanomas (<1 mm thickness) over a median observation period of 4 years (18 to 87 months). In addition to Breslow thickness, Clark level, and growth phase characteristics, we assessed cellular proliferation by counting mitoses and immunohistochemically using the monoclonal antibody Ki-S5 (Ki-67). Mitotic and Ki-S5 indices were correlated to tumor thickness, Clarks level, and radial/vertical growth phase (RGP/VGP). However, 5 tumors had proliferation indices above 25% (outside the range of a theoretical normal distribution). Four of these tumors metastasized, and none of the melanomas with lower proliferative activity progressed during the observation period. The metastatic behavior was independent of tumor thickness and Clark level and did not unconditionally coincide with VGP or high mitotic counts. It is concluded that the immunohistochemical proliferation index may be a powerful predictor of early systemic progression in thin melanomas, which may be helpful in making therapeutic decisions. Further investigations are needed to determine the value of proliferation measurements for the long-term prognosis of thin melanomas. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11774172     DOI: 10.1053/hupa.2001.29658

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Authors:  Rita G Ladstein; Ingeborg M Bachmann; Oddbjørn Straume; Lars A Akslen
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

Review 2.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

3.  Primary oral melanoma: a histopathological and immunohistochemical study of 22 cases of Latin America.

Authors:  Bruno-Augusto-Benevenuto de-Andrade; Víctor-Hugo Toral-Rizo; Jorge-Esquiche León; Elisa Contreras; Román Carlos; Wilson Delgado-Azañero; Adalberto Mosqueda-Taylor; Oslei-Paes de-Almeida
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-05-01

4.  Smouldering malignant melanoma and metastatic dormancy: an update and review.

Authors:  Gérald E Piérard; Claudine Piérard-Franchimont; Marie-Annick Reginster; Pascale Quatresooz
Journal:  Dermatol Res Pract       Date:  2011-11-02

5.  Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.

Authors:  G E Piérard
Journal:  ISRN Dermatol       Date:  2012-01-11

Review 6.  Dormancy of growth-stunted malignant melanoma: sustainable and smoldering patterns.

Authors:  Claudine Piérard-Franchimont; Trinh Hermanns-Lê; Philippe Delvenne; Gerald E Piérard
Journal:  Oncol Rev       Date:  2014-09-23

7.  Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy.

Authors:  Weinan Guo; Huina Wang; Yuqi Yang; Sen Guo; Weigang Zhang; Yu Liu; Xiuli Yi; Jingjing Ma; Tao Zhao; Lin Liu; Zhe Jian; Ling Liu; Gang Wang; Tianwen Gao; Qiong Shi; Chunying Li
Journal:  Theranostics       Date:  2017-06-01       Impact factor: 11.556

Review 8.  Role of Biomarkers in the Integrated Management of Melanoma.

Authors:  Piyu Parth Naik
Journal:  Dis Markers       Date:  2021-12-30       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.